| Current Price | $65.11 | Mkt Cap | $82.0B |
|---|---|---|---|
| Open | $64.82 | P/E Ratio | 665.39 |
| Prev. Close | $65.11 | Div. (Yield) | $2.84 (4.4%) |
| Daily Range | $64.24 - $65.25 | Volume | 5,848,292 |
| 52-Wk Range | $56.56 - $85.79 | Avg. Daily Vol. | 8,013,267 |
A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
| Current Price | $65.11 | Mkt Cap | $82.0B |
|---|---|---|---|
| Open | $64.82 | P/E Ratio | 665.39 |
| Prev. Close | $65.11 | Div. (Yield) | $2.84 (4.4%) |
| Daily Range | $64.24 - $65.25 | Volume | 5,848,292 |
| 52-Wk Range | $56.56 - $85.79 | Avg. Daily Vol. | 8,013,267 |
The best Bull and Bear pitches based on recency and number of recommendations.
This company has proved that it can cure diseases. It has over $30B in cash. Good mgmt. Good yield. As of today at has a P/E of 7. If this company was not here tomorrow, people would notice.
I have a real hard time imagining that Gilead will have sold enough Remdesivir to make this stock a market performer much less a market *beater.* I do continue to own shares in my real portfolio though, so I'm happy to be proven wrong. Underperform.
Read the most recent pitches from players about GILD.
Recs
Dividends500
(85.32)
Submitted: 12/31/2020 11:37:12 PM :
Start Price:
$58.01
NASDAQ:GILD Score:
+2.60
Dividends500 tracks the healthiest dividends in the S&P 500.
To qualify for the portfolio, the company must meet three simple requirements:
- Member of the S&P 500
- Payout ratio below 50%
- Dividend growth year over year
Recs
dusand
(90.94)
Submitted: 12/11/2020 1:46:33 PM :
Start Price:
$59.31
NASDAQ:GILD Score:
-2.85
Looks cheap. This company has several projects with positive surprise potential. Also, the stock price fell to a level where it becomes a value pick.
Recs
TMFjbonefish
(43.33)
Submitted: 11/23/2020 12:46:07 PM :
Start Price:
$58.23
NASDAQ:GILD Score:
+3.63
More data on Remdesivir likely to show it's not very effective; A new administration will undo FDA approval if liver and kidney side effects persist. Increasingly desperate acquisitions at extreme valuations will be hard to generate a return. Finally, the US government is going to take profits or patents related to HIV and hepatitis -- I don't see a way around that severely limiting the company's profit moving forward.
Find the members with the highest scoring picks in GILD.
BrianMotleyFool (72.47) Score: +536.73
The Score Leader is the player with the highest score across all their picks in GILD.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| WilliamCrook2003 | 72.28 |
|
|
5Y | $13.12 | +396.30% | +207.17% | +189.13 | 1 Comment | |
| UrineLuck73 | < 20 | 1/29/2007 |
|
NS | $13.12 | +396.30% | +207.17% | +189.13 | 0 Comment | |
| predragj | 42.70 | 1/30/2007 |
|
NS | $13.29 | +390.02% | +206.82% | +183.20 | 0 Comment | |
| mxdfool | < 20 | 12/15/2006 |
|
5Y | $13.35 | +387.78% | +205.76% | +182.02 | 0 Comment | |
| betsypurcell | < 20 | 1/24/2007 |
|
NS | $13.37 | +387.10% | +205.49% | +181.61 | 0 Comment | |
| JSergeant | 75.56 | 7/3/2006 |
|
3Y | $12.42 | +424.07% | +244.01% | +180.06 | 0 Comment | |
| rmarinchek | < 20 | 1/25/2007 |
|
3W | $13.47 | +383.45% | +203.64% | +179.81 | 0 Comment | |
| Redskins2k9 | < 20 | 1/25/2007 |
|
5Y | $13.47 | +383.45% | +203.64% | +179.81 | 0 Comment | |
| opveiby | 78.96 | 1/25/2007 |
|
5Y | $13.47 | +383.45% | +203.64% | +179.81 | 0 Comment | |
| jer8899 | 69.55 | 1/23/2007 |
|
NS | $13.44 | +384.51% | +205.53% | +178.98 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
